Cargando…

PD-L1 expression is associated with advanced non-small cell lung cancer

Lung cancer is the most common cause of cancer-associated mortalities worldwide. Novel immunotherapies have been developed to improve the clinical outcomes of non-small cell lung cancer (NSCLC). Antibodies against programmed cell death protein 1 (PD-1) and programmed cell death protein 1 ligand 1 (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhiquan, Mei, Jiandong, Liu, Lunxu, Wang, Guochen, Li, Zuosheng, Hou, Jingpu, Zhang, Qiuyang, You, Zongbing, Zhang, Liu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950525/
https://www.ncbi.nlm.nih.gov/pubmed/27446371
http://dx.doi.org/10.3892/ol.2016.4741
_version_ 1782443567978905600
author Chen, Zhiquan
Mei, Jiandong
Liu, Lunxu
Wang, Guochen
Li, Zuosheng
Hou, Jingpu
Zhang, Qiuyang
You, Zongbing
Zhang, Liu
author_facet Chen, Zhiquan
Mei, Jiandong
Liu, Lunxu
Wang, Guochen
Li, Zuosheng
Hou, Jingpu
Zhang, Qiuyang
You, Zongbing
Zhang, Liu
author_sort Chen, Zhiquan
collection PubMed
description Lung cancer is the most common cause of cancer-associated mortalities worldwide. Novel immunotherapies have been developed to improve the clinical outcomes of non-small cell lung cancer (NSCLC). Antibodies against programmed cell death protein 1 (PD-1) and programmed cell death protein 1 ligand 1 (PD-L1) have been tested in clinical trials, and anti-PD-1 antibody has been approved for the treatment of NSCLC. The aim of the present study was to assess expression of PD-1, PD-L1 and programmed cell death protein 1 ligand 2 (PD-L2) in 48 patients with NSCLC, using immunohistochemical staining. The results found that 35.4% (17/48) of patients were positive for PD-1 expression, 64.6% (31/48) were positive for PD-L1 expression and 45.8% (22/48) were positive for PD-L2 expression. Neither PD-1 nor PD-L2 expression was associated with gender, histology, differentiation status, tumor stage or lymph node metastasis. PD-L1 expression was not associated with gender, histology, differentiation status or lymph node metastasis; however, PD-L1 expression was significantly increased in stage III NSCLC (85.7% PD-L1+) compared with stage I/II NSCLC (55.9% PD-L1+) (P=0.049).
format Online
Article
Text
id pubmed-4950525
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-49505252016-07-21 PD-L1 expression is associated with advanced non-small cell lung cancer Chen, Zhiquan Mei, Jiandong Liu, Lunxu Wang, Guochen Li, Zuosheng Hou, Jingpu Zhang, Qiuyang You, Zongbing Zhang, Liu Oncol Lett Articles Lung cancer is the most common cause of cancer-associated mortalities worldwide. Novel immunotherapies have been developed to improve the clinical outcomes of non-small cell lung cancer (NSCLC). Antibodies against programmed cell death protein 1 (PD-1) and programmed cell death protein 1 ligand 1 (PD-L1) have been tested in clinical trials, and anti-PD-1 antibody has been approved for the treatment of NSCLC. The aim of the present study was to assess expression of PD-1, PD-L1 and programmed cell death protein 1 ligand 2 (PD-L2) in 48 patients with NSCLC, using immunohistochemical staining. The results found that 35.4% (17/48) of patients were positive for PD-1 expression, 64.6% (31/48) were positive for PD-L1 expression and 45.8% (22/48) were positive for PD-L2 expression. Neither PD-1 nor PD-L2 expression was associated with gender, histology, differentiation status, tumor stage or lymph node metastasis. PD-L1 expression was not associated with gender, histology, differentiation status or lymph node metastasis; however, PD-L1 expression was significantly increased in stage III NSCLC (85.7% PD-L1+) compared with stage I/II NSCLC (55.9% PD-L1+) (P=0.049). D.A. Spandidos 2016-08 2016-06-16 /pmc/articles/PMC4950525/ /pubmed/27446371 http://dx.doi.org/10.3892/ol.2016.4741 Text en Copyright: © Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Chen, Zhiquan
Mei, Jiandong
Liu, Lunxu
Wang, Guochen
Li, Zuosheng
Hou, Jingpu
Zhang, Qiuyang
You, Zongbing
Zhang, Liu
PD-L1 expression is associated with advanced non-small cell lung cancer
title PD-L1 expression is associated with advanced non-small cell lung cancer
title_full PD-L1 expression is associated with advanced non-small cell lung cancer
title_fullStr PD-L1 expression is associated with advanced non-small cell lung cancer
title_full_unstemmed PD-L1 expression is associated with advanced non-small cell lung cancer
title_short PD-L1 expression is associated with advanced non-small cell lung cancer
title_sort pd-l1 expression is associated with advanced non-small cell lung cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950525/
https://www.ncbi.nlm.nih.gov/pubmed/27446371
http://dx.doi.org/10.3892/ol.2016.4741
work_keys_str_mv AT chenzhiquan pdl1expressionisassociatedwithadvancednonsmallcelllungcancer
AT meijiandong pdl1expressionisassociatedwithadvancednonsmallcelllungcancer
AT liulunxu pdl1expressionisassociatedwithadvancednonsmallcelllungcancer
AT wangguochen pdl1expressionisassociatedwithadvancednonsmallcelllungcancer
AT lizuosheng pdl1expressionisassociatedwithadvancednonsmallcelllungcancer
AT houjingpu pdl1expressionisassociatedwithadvancednonsmallcelllungcancer
AT zhangqiuyang pdl1expressionisassociatedwithadvancednonsmallcelllungcancer
AT youzongbing pdl1expressionisassociatedwithadvancednonsmallcelllungcancer
AT zhangliu pdl1expressionisassociatedwithadvancednonsmallcelllungcancer